Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Comment by SurfForWealthon Nov 26, 2003 3:47pm
417 Views
Post# 6703056

RE: New investor

RE: New investorWe just picked up some more shares at $2.00. Looking at FY2004 (Oct 31), we can estimate earnings from the following, payment collected of $3.9M plus approximately $3.25M from product sales gives us revenue of $7.15M. The CEO estimated the expenses for FY2004 at $3M but lets give a margin of error & use $3.5M gives us net earnings of $3.65M or 12 cents per share for a P/E multiple of 16.7 ($2.00). While there may not be a lump sum payment in FY2005, it seems reasonable to expect product revenues to ramp up rather quickly, if the first gen uPM3 is so effective. Therefore it is possible that the earnings for FY2005 could be as good or better as FY2004. Then in FY2006, if the second gen uPM3 hits the market, CUR could see earnings explode upwards. It seems feasible that the stock could potentially be trading for 10 times it's current value within 2-3 years. Is my logic missing something? Are there other considerations that I may have overlooked? darv, you seem to be well informed on this company....can you answer my earlier questions please? TIA Cheers!!!
Bullboard Posts